Psoriatic arthritis: The role of TNF inhibition and the effect of its inhibition with etanercept

Clinical and Experimental Rheumatology

Volumn 20, Issue 6 SUPPL. 28, 2002, Pages

  Mease, Philip ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Controlled clinical trial; Cytokine; Etanercept; Psoriasis; Psoriatic arthritis; Tumor necrosis factor

Indexed keywords

CALCIPOTRIOL; CYCLOSPORIN; ETANERCEPT; IMMUNOGLOBULIN; LYMPHOTOXIN; METHOTREXATE; PLACEBO; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; BIOLOGICAL RESPONSE MODIFIER; IMMUNOGLOBULIN G; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN;

ANTIBODY STRUCTURE; ARTICLE; CASE STUDY; CHRONIC ARTHRITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; DRUG ANTAGONISM; REVIEW;

ARTHRITIS, PSORIATIC; BIOLOGICAL RESPONSE MODIFIERS; HUMANS; IMMUNOGLOBULIN G; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036400958     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. GLADMAN DD, STAFFORD-BRADY F, CHANG C-H, LEWANDOWSKI K, RUSSELL ML: Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990; 17: 809-12.
2. TORRE-ALONSO JC, RODRIGUEZ PEREZ A, ARRIBAS CASTRILLO JM, BALLINA GARCIA J, RIESTRA NORIEGA JL, LOPEZ LARREA C: Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol 1991; 30: 245-50.
3. JONES G, CROTTY M, BROOKS P: Interventions for treating psoriatic arthritis (Cochrane Review). In: The Cochrane Library. Issue 1. Oxford, Update Software; 2001.
4. PARTSCH G, STEINER G, LEEB BF, DUNKY A, BRÖLL H, SMOLEN JS: Highly increased levels of tumor necrosis factor-α and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997; 24: 518-23.
5. HUSBY G, WILLIAMS RC Jr: Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis. J Autoimmun 1988; 1: 363-71.
6. DELEURAN BW, CHU CQ, FIELD M et al.: Localization of interleukin-1α, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Br J Rheumatol 1992; 31: 801-9.
7. RITCHLIN C, HAAS-SMITH SA, HICKS D, CAPPUCCIO J, OSTERLAND CK, LOONEY RJ; Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998; 25: 1544-52.
8. NAWROTH PP, BANK I, HANDLEY D, CASSIMERIS J, CHESS L, STERN D Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med 1986; 163: 1363-75.
9. BRENNAN FM, CHANTRY D, JACKSON A, MAINI R, FELDMANN M: Inhibitory effect of TNF-α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989; 2: 244-7.
10. BUTLER DM, MAINI RN. FELDMANN M, BRENNAN FM: Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-α antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw 1995; 6: 225-30.
11. HAWORTH C, BRENNAN FM, CHANTRY D, TURNER M, MAINI RN, FELDMANN M: Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-α. Eur J Immunol 1991; 21: 2575-9.
12. SAKLATVALA J: Turnout necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986; 322: 547-9.
13. BERTOLINI DR, NEDWIN GE, BRINGMAN TS, SMITH DD, MUNDY GR: Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 1986; 319: 516-8.
14. SHINMEI M, MASUDA K, KIKUCHI T, SHIMOMURA Y: The role of cytokines in chondrocyte mediated cartilage degradation. J Rheumatol 1989; 6 (Suppl. 18): 32-4.
15. 2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985; 162: 2163-8.
16. PARTSCH G, WAGNER E, LEEB BF, DUNKY A, STEINER G, SMOLEN JS: Upregulation of cytokine receptors sTNF-R55, sTNF-R75, and sIL-2R in psoriatic arthritis synovial fluid. J Rheumatol 1998; 25: 105-10.
17. COPE AP, ADERKA D, DOHERTY M et al.: Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 1992; 35: 1160-9.
18. ROUX-LOMBARD P, PUNZI L, HASLER F et al.: Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum 1993; 36: 485-9.
19. MOHLER KM, TORRANCE DS, SMITH CA et al.: Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993; 151: 1548-61.
20. ENBREL® [package insert]. Seattle, Wash: Immunex Corporation; 2002.
21. RUDDLE NH: Lymphoid neo-organogenesis: lymphotoxin's role in inflammation and development. Immunol Res 1999; 19: 119-25.
22. BARONE D, KRANTZ C, LAMBERT D, MAGGIORA K, MOHLER K: Comparative analysis of the ability of etanercept and infliximab to lyse TNF-expressing cells in a complement dependent fashion [abstract]. Arthritis Rheum 1999; 42 (Suppl.): S90.
23. MEASE PJ, GOFFE BS, METZ J, VANDERSTOEP A, FINCK B, BURGE DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. Lancet 2000; 356: 385-90.
24. MEASE PJ, GOFFE BS, METZ J, VANDERSTOEP A, BURGE DJ: Enbrel® (etanercept) in patients with psoriatic arthritis and psoriasis [poster]. Presented at: European League Against Rheumatism (EULAR)/European Congress of Rheumatology, June 13-16, 2001; Prague, Czech Republic.
25. MEASE P, KIVITZ A, BURCH F, SIEGEL E, COHEN S, BURGE D: Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (Enbrel®): Results of a phase 3 multicenter clinical trial [abstract]. Arthritis Rheum 2001; 44 (Suppl.): S90.
26. GOTTLIEB AB, LOWE NJ, MATHESON RT, LEBSACK ME: Efficacy of etanercept in patients with psoriasis [poster]. Presented at: American Academy of Dermatology, February 24-26, 2002, New Orleans, LA.
27. KURSCHAT P, RUBBERT A, POSWIG A, SCHARFFETTER-KOCHANEK K, KRIEG T, HUNZELMANN N: Treatment of psoriatic arthritis with etanercept [letter]. J Am Acad Dermatol 2001; 44: 1052.
28. ELKAYAM O, YARON M, CASPI D: From wheels to feet: a dramatic response of severe chronic psoriatic arthritis to etanercept [letter]. Ann Rheum Dis 2000; 59: 839.
29. YAZICI Y, ERKAN D, LOCKSHIN MD: A preliminary study of etanercept in the treatment of severe, resistant psoriatic arthritis. Clin Exp Rheumatol 2000; 18: 732-4.
30. CUELLAR ML, MENDEZ EA, COLLINS RD, BURFORD S, ESPINOZA LR: Efficacy of etanercept in refractory psoriatic arthritis (PsA) [abstract]. Presented at: 64th Annual Scientific Meeting of the American College of Rheumatology and the 35th Annual Scientific Meeting of the Association of Rheumatology Health Professionals, October 28 - November 2, 2000, Philadelphia, Pa. Abstract 235.
31. IYER S, YAMAUCHI P, LOWE NJ: Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol 2002; 146: 118-21.
32. YAZICI Y, ERKAN D, LOCKSHIN MD: Etanercept in the treatment of severe, resistant psoriatic arthritis: Continued efficacy and changing patterns of use after two years [letter]. Clin Exp Rheumatol 2002; 20: 115.
33. ABOULAFIA DM, BUNDOW D, WILSKE K, OCHS UI: Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis. Mayo Clin Proc 2000: 75: 1093-8.
34. BATHON JM, MARTIN RW, FLEISCHMANN RM et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [published errata appear in N Engl J Med 2001; 344: 76 and N Engl J Med 2001; 344: 240]. N Engl J Med 2000; 343: 1586-93.
35. MORELAND LW, COHEN SB, BAUMGARTNER SW, SCHIFT MH, TINDALL EA, BURGE DJ: Long-term use of Enbrel® (etanercept) in patients with DMARD-refractory rheumatoid arthritis [abstract]. Presented at: European League Against Rheumatism (EULAR)/European Congress of Rheumatology, June 13-16, 2001, Prague, Czech Republic. Abstract FRI0080.
36. MORELAND LW, COHEN SB, BAUMGARTNER SW et al.: Longterm safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001; 28: 1238-44.
37. KREMER JM, WEINBLATT ME, FLEISCHMANN RM, BANKHURST AD, BURGE DJ: Etanercept (Enbrel®) in addition to methotrexate (MTX) in rheumatoid arthritis (RA): Long-term observations [abstract]. Arthritis Rheum 2001; 44 (Suppl.): S78.
38. CLEGG DO, REDA DJ, MEJIAS E et al.: Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39: 2013-20.
39. FELSON DT, ANDERSEN JJ, BOERS M et al.: American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
40. FREDRIKSSON T: Oral treatment of psoriasis and pustulosis palmo-plantaris with Ro 10-9359. Dermatologica 1978; 157 (Suppl. 1): 13-18.
41. FRANKLIN CM: Clinical experience with soluble TNF p75 receptor in rheumatoid arthritis. Semin Arthritis Rheum 1999; 29: 172-82.